Archives

`s-Hertogenbosch, the Netherlands; 08 December 2021. Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, announces significant progress in its two clinical programs in pancreatic cancer as well as the full recruitment of all patients in its pivotal Phase II/III study in mesothelioma.

Based on a preliminary efficacy analysis of the first cohort of the REACtiVe study in resected pancreatic cancer patients, an expansion cohort has been completed at a remarkable pace with results expected in H2 2022. In total 26 patients are now included in the study. Safety and efficacy data from the first cohort of